GenScript Launches Neoantigen Specific Peptide Synthesis Service for Precision Immuno-oncology Therapeutic Development

GenScript USA Inc., a world leading biotechnology company, today announced the commercial launch of its neoantigen peptide synthesis service for biotech and pharma companies developing personalized cancer therapeutics. The service builds on GenScript's work over the past year producing 2,500 highly difficult neoantigen peptides for more than 50 of the world's leading immuno-oncology companies. Unlike traditional targets such as tumor-associated antigens, neoantigens are novel peptides only present within tumor cells and not in healthy tissue. Because of this, neoantigen-based immunotherapy